Aizen is showing strong performance. It appears that news of the resurgence of COVID-19 has had an impact.
As of 10:07 AM on the 21st, Aizen was trading at 3,945 KRW, up 315 KRW (8.68%) compared to the previous trading day.
Recently, Aizen began the first administration in the Phase 2a clinical trial in Australia for its mRNA-based COVID-19 booster vaccine.
This clinical trial aims to evaluate the immunogenicity of the COVID-19 vaccine ‘EasyCovid’ and the Omicron variant prevention vaccine ‘EasyCovaro.’
The trial is conducted on 46 healthy adults aged 18 and over who have a history of COVID-19 vaccination. EasyCovid 400㎍ (micrograms) and 800㎍, and EasyCovaro 800㎍ are each administered twice at three-week intervals as additional booster shots. Antibody changes will be measured afterward to confirm booster efficacy.
Previously, Aizen conducted an interim analysis of Phase 1 booster clinical trial results for EasyCovid. Approximately half of the clinical subjects showed efficacy exceeding 80%.
According to Aizen, government support for securing domestic vaccine sovereignty continues. Aizen’s mRNA-based COVID-19 vaccine technology was selected last year for the national project ‘Support for Clinical Trials of mRNA Vaccines Responding to New Infectious Diseases.’ It will receive a total of 10 billion KRW in government support by next year.
Meanwhile, according to the Central Disease Control Headquarters (CDCH) on the 19th, new confirmed cases in the second week of July reached 186,953, an increase of 22.2% compared to the previous week. The weekly average daily confirmed cases have been rising for three consecutive weeks, from 16,025 in the third week of June to 26,708 in the second week of July. Daily new confirmed cases exceeded 30,000 for the first time in six months on the 11th, recording 31,224 since January 27.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
